Evaxion to announce business update and full year 2025 financial results on March 5, 2026

Core Insights - Evaxion A/S is set to provide a business update and report its full year 2025 financial results on March 5, 2026, before the opening of Nasdaq CM [1] - The company's Executive Management will host a conference call and webcast on the same day at 14:30 CET/08:30 EST to present the update and results, along with a Q&A session [1] Company Overview - Evaxion is a clinical-stage TechBio company that utilizes its proprietary AI-Immunology™ platform to develop novel vaccines targeting cancer and infectious diseases [3][4] - The AI-Immunology™ platform enables rapid and efficient target discovery, drug design, and development, supported by a team of over 40 experts [4] Product Pipeline - The company has developed a clinical pipeline that includes both personalized and off-the-shelf cancer vaccine candidates, as well as prophylactic vaccine candidates for infectious diseases [4] - All vaccine candidates aim to address high unmet medical needs, reflecting the company's commitment to transforming patients' lives through innovative treatment options [4]